How big is the Pet Cancer Therapeutics Market?

The Pet Cancer Therapeutics Market size is expected to reach USD 444.10 million in 2024 and grow at a CAGR of 7.91% to reach USD 649.82 million by 2029. Read More

What is the current Pet Cancer Therapeutics Market size?

In 2024, the Pet Cancer Therapeutics Market size is expected to reach USD 444.10 million. Read More

Who are the key players in Pet Cancer Therapeutics Market?

Boehringer Ingelheim GmbH (Merial), Zoetis, Elanco (VetDC), ELIAS Animal Health and Vivesto AB (AdvaVet, Inc) are the major companies operating in the Pet Cancer Therapeutics Market. Read More

Which is the fastest growing region in Pet Cancer Therapeutics Market?

Asia Pacific is estimated to grow at the highest CAGR over the forecast period (2024-2029). Read More

Which region has the biggest share in Pet Cancer Therapeutics Market?

In 2024, the North America accounts for the largest market share in Pet Cancer Therapeutics Market. Read More

What years does this Pet Cancer Therapeutics Market cover, and what was the market size in 2023?

In 2023, the Pet Cancer Therapeutics Market size was estimated at USD 411.55 million. The report covers the Pet Cancer Therapeutics Market historical market size for years: 2021, 2022 and 2023. The report also forecasts the Pet Cancer Therapeutics Market size for years: 2024, 2025, 2026, 2027, 2028 and 2029. Read More

Pet Cancer Therapeutics Market Report | Industry Analysis, Size & Growth Insights

Pet Cancer Therapeutics Market Size & Share Analysis - Growth Trends & Forecasts (2024 - 2029)

The Report Covers Pet Cancer Treatment Market and it is Segmented by Therapy (Chemotherapy, Radiation therapy, Immunotherapy, Targeted Therapy, and Other Therapies), Animal (Dogs, Cats, Other Animals), Application (Lymphoma, Mast Cell Cancer, Melanoma, Mammary, and Squamous Cell Cancer, Other Applications), and Geography (North America, Europe, Asia-Pacific, Middle East and Africa, and South America). The market provides the value (in USD million) for the above segments.

Pet Cancer Therapeutics Industry Overview

The pet cancer therapeutics market is slightly consolidated in nature due to the presence of a few companies operating globally as well as regionally. The competitive landscape includes an analysis of a few international as well as local companies which hold market shares and are well known. Some key market players are AB Science, Vivesto AB (AdvaVet, Inc), Boehringer Ingelheim GmbH (Merial), Elanco (VetDC), ELIAS Animal Health, Karyopharm Therapeutics, Inc., Dechra Pharmaceuticals PLC (Anivive Lifesciences), Torigen Pharmaceuticals Inc., Elekta, Virbac, Norbrook, and Zoetis among others.